Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01803009 · ClinicalTrials.gov registry record · NA
Patients' Opinions and Responses to the National Cancer Institute's Colorectal Cancer Risk Assessment Tool
A NA study of Colorectal Cancer, sponsored by Indiana University.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT01803009: Completed NA study of Colorectal Cancer, sponsored by Indiana University.
NCT01803009 is a NA study of Colorectal Cancer that has completed, run by Indiana University. The registered enrollment target is 63 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01803009, a NA study of Colorectal Cancer, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
Little is known about the impact of risk assessment tools on decision-making by patients and clinicians. In particular, even though the NCI Colorectal Cancer Risk Assessment Tool is one of the most prominent risk assessment tools available, no study has quantified its usability or impact on decision-making or uptake of screening. In this study, we will measure patients' satisfaction with the NCI CRC RAT, their perception of its usability and helpfulness, and its impact on their decision-making and behavior. In addition, we will assess the impact of adding information about their chance of having an advanced adenoma.
Primary Outcome
19 Likert-scale questions regarding usability of and satisfaction with the questions asked by the website to assess individual risk and the information provided
Conditions Studied
Interventions
- BEHAVIORAL Patient views NCI CRC RAT
- BEHAVIORAL View presentation regarding current chance of having an advanced adenoma
Study Locations (1)
Indiana
- Indiana University Health - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-10 |
| Phase | NA |
What the finished NCT01803009 record still lists
NCT01803009 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Patient views NCI CRC RAT is the first listed.
NCT01803009 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT01803009 about?
NCT01803009 is a clinical study titled "Patients' Opinions and Responses to the National Cancer Institute's Colorectal Cancer Risk Assessment Tool". Little is known about the impact of risk assessment tools on decision-making by patients and clinicians. In particular, even though the NCI Colorectal Cancer Risk Assessment Tool is one of the most prominent risk assessment tools available, no study has quantified its usability or impact on decision...
What is the current status of trial NCT01803009?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2012-11. Estimated completion is 2013-10.
What conditions does trial NCT01803009 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT01803009?
The interventions under investigation include: Patient views NCI CRC RAT (BEHAVIORAL), View presentation regarding current chance of having an advanced adenoma (BEHAVIORAL).
Who is sponsoring clinical trial NCT01803009?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01803009 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01803009's enrollment target sits among peer trials
63 255th of 381 higher than 127 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
RECRUITING · NA
-
Ultrasound and Photoacoustic Imaging for Enhanced Differential Diagnosis of Rectal Cancer
RECRUITING · NA
-
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia